Велирег
(Белзутифан)
(40 mg)
(90)
(Талетки)
Welireg (belzutifan) 40 mg, 90 tablets, generic
In Stock
Indication
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.1. It is also approved for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).5
-
Commercial name:Велирег
-
Сhemical name:Белзутифан
-
Dosage:40 mg
-
Quantity:90
-
Release form:Талетки
-
Производитель:Бангладешь
No reviews yet